About
Research
Publications
2026
Glycan analysis of serum and breast tissue identifies potential biomarkers of cancer subtype and severity
Kamili N, Elliot C, Funkhouser A, Alam I, Martin J, Valafar H, Lasanajak Y, Song X, Arthur C, Edenfield W, Blenda A. Glycan analysis of serum and breast tissue identifies potential biomarkers of cancer subtype and severity. BMC Cancer 2026 PMID: 41965548, DOI: 10.1186/s12885-026-15964-w.Peer-Reviewed Original ResearchMolecular subtypesHealthy controlsGlycan analysisER-negative tumorsMALDI-TOF mass spectrometryPoor differentiation gradePotential biomarkersBreast cancer pathogenesisBreast cancer patientsAdvanced cancer stageBreast cancer diagnosticsAnalysis of serumHER2-positiveAccurate stagingGlycomic profilingMass spectrometryDifferentiation gradeSerum levelsInvasive biopsyCancer stageCancer subtypesBackgroundBreast cancerCancer patientsDisease progressionMalignant tissues
2024
Medical Student Preferences on Examination Scheduling at a US Allopathic Medical School – Survey Study
Funkhouser A, Blenda A. Medical Student Preferences on Examination Scheduling at a US Allopathic Medical School – Survey Study. Advances In Medical Education And Practice 2024, 15: 945-955. PMID: 39403560, PMCID: PMC11472763, DOI: 10.2147/amep.s459701.Peer-Reviewed Original ResearchCorrelation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients
Markalunas E, Arnold D, Funkhouser A, Martin J, Shtutman M, Edenfield W, Blenda A. Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. Genes 2024, 15: 818. PMID: 38927753, PMCID: PMC11203217, DOI: 10.3390/genes15060818.Peer-Reviewed Original ResearchConceptsSerum galectin-3 levelsGalectin-3 levelsBreast cancer samplesTP53 mutationsCancer-critical genesElevated serum levelsBreast cancer patientsGalectin levelsEnzyme-linked immunosorbent assayGenetic mutationsTP53Cancer samplesSerum levels of galectin-9Cancer patientsDisease progressionPatient seraDuctal carcinoma in situAnalysis of genetic mutationsLevels of galectin-9Galectin-1Genomics core facilityPrimary breast cancer samplesAssociated with disease progressionSerum galectin levelsEffects of genetic mutationsExploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer
Shuster H, Funkhouser A, Allen L, Heo M, Martin J, Edenfield W, Blenda A. Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer. Cancers 2024, 16: 1165. PMID: 38539500, PMCID: PMC10969284, DOI: 10.3390/cancers16061165.Peer-Reviewed Original ResearchNon-small cell lung cancerSurgically resected non-small cell lung cancerResected non-small cell lung cancerCell lung cancerGalectin-1 levelsOverall survivalLung cancerEnzyme-linked immunosorbent assayNon-small cell lung cancer patientsPatients exposed to chemotherapySquamous cell lung cancerCancer treatmentRetrospective chart reviewGalectin-1Galectin-3Galectin-3 levelsSerum galectin-1Patient demographicsTumor biologyPrognostic markerChart reviewNon-smallCancer stageMultivariate analysisGalectin levels
2023
Pattern Analysis of Serum Galectins-1, -3, and -9 in Breast Cancer
Funkhouser A, Shuster H, Martin J, Edenfield W, Blenda A. Pattern Analysis of Serum Galectins-1, -3, and -9 in Breast Cancer. Cancers 2023, 15: 3809. PMID: 37568625, PMCID: PMC10417135, DOI: 10.3390/cancers15153809.Peer-Reviewed Original ResearchEnzyme-linked immunosorbent assayHormone-receptor-positive tumorsEvasion of immune destructionHER2-enriched tumorsBreast cancer patientsResponse to treatmentSerum of patientsProgression of cancerReceptor expressionGalectin-1Molecular subtypesTumor biologyImmune destructionBreast cancerSerum concentrationsCancer patientsGalectin levelsTumorCancer progressionPatientsGalectin-9Therapeutic targetImmunosorbent assayCancerMolecular phenotypes
2022
Comprehensive and User-Analytics-Friendly Cancer Patient Database for Physicians and Researchers
Firooz A, Funkhouser A, Martin J, Edenfield W, Valafar H, Blenda A. Comprehensive and User-Analytics-Friendly Cancer Patient Database for Physicians and Researchers. 2022, 00: 1615-1621. DOI: 10.1109/csci58124.2022.00289.Peer-Reviewed Original ResearchClinical courseClinical course of cancerIndividualized treatmentCombination of genetic mutationsCancer patient databasePatient clinical dataIndividual cancer patientsCourse of cancerSerum levelsClinical patternPrognostic powerClinical dataGene mutationsCancer stageGlycomic profilingCo-morbiditiesCancer patientsNeoplastic mutationsGeneral health statusCancer patient careGlycan compositionInteraction databasesGenetic mutationsPatientsPatient databaseEducational Case: Histoplasmosis
Funkhouser A, Huppmann A. Educational Case: Histoplasmosis. Academic Pathology 2022, 9: 100060. PMID: 36386563, PMCID: PMC9649936, DOI: 10.1016/j.acpath.2022.100060.Peer-Reviewed Original ResearchAcetaminophen Disrupts the Development of Pharyngeal Arch-Derived Cartilage and Muscle in Zebrafish
Glasco D, Wang Z, Kang S, Funkhouser A. Acetaminophen Disrupts the Development of Pharyngeal Arch-Derived Cartilage and Muscle in Zebrafish. Journal Of Developmental Biology 2022, 10: 30. PMID: 35893125, PMCID: PMC9326545, DOI: 10.3390/jdb10030030.Peer-Reviewed Original ResearchPharyngeal arch developmentNeural crest cellsAcetaminophen treatmentArch developmentCrest cellsLethal doseDose of acetaminophenLethal dose of acetaminophenEffects of acetaminophenCraniofacial cartilage defectsCraniofacial cartilage developmentCranial neural crest cellsCraniofacial musclesCartilage defectsEarly embryonic developmentCraniofacial developmentPharyngeal archesCraniofacial cartilageNeural crestLiver developmentAcetaminophenCartilage differentiationEmbryonic developmentCartilageCartilage developmentKIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer
Funkhouser A, Strigenz A, Blair B, Miller A, Shealy J, Ewing J, Martin J, Funk C, Edenfield W, Blenda A. KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer. Cancers 2022, 14: 2781. PMID: 35681762, PMCID: PMC9179545, DOI: 10.3390/cancers14112781.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerC-kit proteinCancer patientsBrain metastasesSerum levelsReceptor tyrosine kinasesC-kitLung cancerLevels of galectinsNon-small cell lung cancer patientsCell lung cancer patientsTyrosine kinaseBreast cancer patientsLung cancer patientsAnti-cancer treatmentComposition of cancer cellsCancer-critical genesGlycocalyx compositionMetastatic diseaseKIT mutationsMutation statusPrimary cancerSerum galectinsProtein trafficking
2021
Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis
Sansone A, Hisrich B, Young R, Abel W, Bowens Z, Blair B, Funkhouser A, Schammel D, Green L, Lessey B, Blenda A. Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis. Current Issues In Molecular Biology 2021, 43: 1350-1360. PMID: 34698105, PMCID: PMC8929102, DOI: 10.3390/cimb43030096.Peer-Reviewed Original ResearchConceptsB-cell lymphoma 6Non-invasive diagnostic markersEnzyme-linked immunoassayPresence of endometrial glandsDiagnostic markers of endometriosisAdvanced stage III/IVAssociated with severe pelvic painNon-invasive diagnostic testsSevere pelvic painMarkers of endometriosisStages of endometriosisEndometrium of womenH-score valuesSirtuin 1Endometrial biopsy samplesStatistically significant elevationPelvic painStage III/IVStage I/IIEndometrial biopsyNo significant differenceSirtuin 1 levelsEndometrial glandsCervical mucusLymphoma 6